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Background: Insulin action has been reported to be normal in type 1 diabetic patients. 
However, some studies have reported an insulin resistance state in these patients. The aim of 
this study was to investigate insulin resistance in a group of type 1 diabetic patients. We studied 
the insulin action in adipose tissue and analyzed the effects of duration of disease, body mass 
index (BMI), and glycosylated hemoglobin on insulin action at the receptor and postreceptor 
levels in adipocytes.
Methods: Nine female type 1 diabetic patients with different durations of disease and eight 
nondiabetic female patients of comparable age and BMI were studied. 125I-insulin binding and 
U-[14C]-D-glucose transport was measured in a sample of subcutaneous gluteus adipose tissue 
obtained by open surgical biopsy from each subject.
Results: The duration of disease was negatively correlated with both 125I-insulin binding capacity 
(r = −0.70, P , 0.05) and basal and maximum insulin-stimulated glucose transport (r = −0.87, 
P , 0.01, and r = −0.88, P , 0.01, respectively). Maximum specific 125I-insulin binding to the 
receptors in adipocytes was higher in the group of patients with a shorter duration of disease 
(P , 0.01). Basal and maximum insulin-stimulated glucose transport was significantly higher 
in the group with less than 5 years of disease (P , 0.01). No correlation was found between 
BMI and insulin action.
Conclusion: Female type 1 diabetic patients have normal insulin action. There is a high glucose 
uptake in the early phase of the disease, although a longer duration of disease appears to be a 
contributing factor to a decrease in insulin action in these patients, and involving both receptor 
and postreceptor mechanisms.
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Introduction
Type 1 diabetes is an organ-specific autoimmune disease caused by altered immune 
tolerance to specific proteins, with selective destruction of insulin-producing beta cells 
in genetically predisposed individuals.1 In contrast, insulin resistance is considered to 
be the main pathophysiological factor for type 2 diabetes.2
Type 1 diabetes patients have less cardiovascular disease than those who suffer 
from type 2 diabetes. However, a higher cardiovascular risk, as well as greater insulin 
resistance, has been reported in type 1 diabetes patients with a positive family history of 
type 2 diabetes compared with type 1 diabetic patients with no family history of type 2 
diabetes.3 Several authors have shown that both hyperinsulinism and insulin resistance 
could explain why patients with type 2 diabetes generally have more   macrovascular 
disease than those with type 1 diabetes.4,5International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Normal insulin action has been reported in type 1 
diabetes.3 In contrast, other studies have described insulin 
resistance in these individuals, with remission after a variable 
follow-up of disease. Prevention of insulin resistance in type 1 
diabetes has recently been recommended. In overweight adult 
type 1 diabetes patients or in those with increased insulin 
resistance, insulin sensitizers could be adequate in addition 
to insulin therapy.6 This rationale would lead to a diminished 
risk of macrovascular disease and subsequently to a lower 
cardiovascular risk in these patients.
We have studied insulin action in type 1 diabetes patients 
and evaluated the effect of glycemic control, body mass index 
(BMI), and time of duration of disease on insulin action in 
these patients.
Materials and methods
Patients
Nine female patients with type 1 diabetes were recruited 
from endocrine clinics. A fasting and glucagon-stimulated 
C-peptide level ,1 ng/dL, as well as positivity for islet-cell 
(IA2) and anti-GAD65 antibodies, were used as diagnostic 
criteria for type 1 diabetes. The duration of disease ranged 
from 4 months to 10 years. None of the patients were on 
  medications that could alter insulin action, apart from 
  exogenous insulin itself. A group of eight healthy women 
matched for age and BMI, and with a normal glucose 
response to an oral glucose tolerance test 2 hours after an 
overload of glucose 75 g, comprised the control group. Their 
BMIs ranged from 20 to 28 kg/m². The study was approved 
by the local ethics committee of the hospital and written 
informed consent was obtained from all the participants 
before entering the study.
Adipocyte isolation
An open surgical biopsy was performed in every patient 
to obtain subcutaneous gluteus adipose tissue for the mea-
surement of  125I-insulin binding, and U-[14C]-D-glucose 
  transport (New Research Products, Dupont de Nemours, 
GmbH, Bad Homburg, Germany). Adipocytes were 
  isolated by the method described by Rodbel and   modified 
by Pedersen et al,7 and insulin binding was measured by 
the method described by Sinha et al.8 Fat tissue in the 
  gluteus region was digested with collagenase 1.5 mg/dL in 
10 mmol HEPES Krebs-Ringer bicarbonate (KRB) buffer, 
pH 7.4, containing 3% bovine serum albumin-KRB buffer, 
for 30–45 minutes at 37°C, under a 95% oxygen/5% CO2 
  atmosphere with   continuous shaking. Cells were filtered 
through a nylon mesh and washed with 1% bovine serum 
albumin-KRB buffer. An aliquot of the cell suspension 
was fixed overnight in 10% formalin-buffered phosphate to 
  determine cell size. Another aliquot was stained with trypan 
blue to determine viability of the adipose cells.
Insulin binding to adipocytes
Fresh adipocytes were incubated with 10 mol/L 125I-insulin 
in the absence and presence, respectively, of increasing 
concentrations of unlabeled insulin (0–10−7 mol/L) at 22°C, 
in a final volume of 1 mL 3% bovine serum albumin-KRB 
buffer for 45 minutes. Aliquots of 250 µL were centrifuged 
through phthalate of bis-(2-ethyl-hexile), and cell-associated 
radioactivity was counted. Specific binding was determined 
after subtracting the nonspecific value obtained in the pres-
ence of 10−6 M of insulin.
Glucose transport
U-[14C]-D-glucose uptake by the cell as described by 
  Kashiwagi et al was used for measuring glucose transport 
into the adipocyte.9 Isolated adipocytes were incubated with 
500 nmol/L U-[14C]-D-glucose in the absence and presence 
of insulin (0–10−7 mol/L) in a final volume of 1 mL 3% 
bovine serum albumin-KRB buffer for 60 minutes, at 37°C 
and under a 95% O2/5% CO atmosphere, with continuous 
shaking. Centrifugation was used to separate the cells and 
three 250 µL aliquots were used for the insulin binding 
assay. No specific glucose transport value was subtracted 
from each value.
Biochemical variables
Serum insulin and C-peptide levels were measured by 
a commercial radioimmunoanalysis kit (Incstar Corp, 
Stillwater, MN). Glycosylated hemoglobin (HbA1c) levels 
were measured by high-performance liquid chromatography 
(Diamat, Bio-Rad, Vienna, Austria) using a Merck-Hitachi 
model L9100 autoanalyzer. Both intra-assay and interassay 
variability were below 10%.
statistical analysis
Data were analyzed using nonparametric tests. For the com-
parison between both individual data and between groups, 
and also between patient subgroups segregated by duration 
of disease, we used the Mann-Whitney U and Wilcoxon tests 
as indicated. The Spearman bivariate correlation analysis was 
used for assessment of the influence of diabetes duration and 
HbA1c levels on the different variables. Data are presented 
as means ± standard deviation, and a P value of ,0.05 was 
considered to be statistically significant. Calculations were International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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performed using the Statistical Package for Social Science 
(SPSS), version 12.0.
Results
Nine type 1 diabetic women (mean age 33 ± 12. years, BMI 
23.9 ± 5.0 kg/m², HbA1c 6.5 ± 0.9%), and eight healthy 
women of comparable age and BMI were studied. Clinical 
features of the study subjects are shown in Table 1.
Maximal insulin binding to adipocytes (5.8 ± 0.4 versus 
6.4 ± 1.3% B/50,000 cells), basal glucose transport (71.7 ± 34 
versus 54.38 ± 38 Fl/cel/s), and maximum insulin-stimulated 
(10−7 mol/L insulin) glucose transport (135.3 ± 74 versus 
102.5 ± 47 Fl/cel/s) were similar in the type 1 diabetic and 
control groups (Table 1).
The whole group of type 1 diabetic patients was segre-
gated into those with up to 5 years of diabetes (n = 5) and 
those with more than 5 years of diabetes (n = 4). Maximum 
specific  125I-insulin binding to the receptor in adipocytes 
(P , 0.01), basal glucose transport (P , 0.05), and maximal 
insulin-stimulated glucose transport (P , 0.01) were higher 
in the former group (Figure 1, Table 2).
When we compared both type 1 diabetes subgroups  with 
the control group, we only found significant differences in 
basal and maximal glucose transport, showing higher values 
in type 1 diabetic patients with less than 5 years of disease 
duration (P , 0.05, Table 2).
Glucose transport showed a significant negative correla-
tion with duration of disease (r = −0.84, P , 0.01). There was 
a negative, but not significant, correlation between HbA1c level 
Table 1 clinical and analytical data for the study groups
T1D patients  
(n = 9)
Controls  
(n = 8)
Body mass  
index (kg/m²)
23.9 ± 5.0 23.8 ± 5.2
hbA1c (%) 6.5 ± 0.9a 4.3 ± 1.0
Fasting plasma  
glucose (mg/dL)
249 ± 100a 83 ± 7
Basal c-peptide (ng/mL) 0.5 ± 0.2a 2.0 ± 1.0
c-peptide at 5 minutes  
after glucagon  
(1 mg.IV) (ng/mL)
0.7 ± 0.3a 5.0 ± 0.9
% maximum  
125I-insulin binding
5.8 ± 0.4 6.4 ± 1.3
Basal U-(14c)-D-glucose  
transport Fl/cel/s
71.4 ± 34 54.3 ± 38
Maximal U-(14c)-D-glucose  
transport after  
10−7 mol/L insulin Fl/cel/s
135.4 ± 74 102.5 ± 47
Notes: Data are means ± standard deviation. aP , 0.01. 
Abbreviations:  IV,  intravenously;  T1D,  type  1  diabetes;  hbA1c,  glycosylated 
hemoglobin.
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Figure 1 Insulin action in the adipocyte: maximal insulin binding and basal and 
maximal glucose transport after stimulated insulin (10−7 mol/L) in type 1 diabetic 
patients with >5 years and ≤ of 5 years of diabetes.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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and insulin binding (r = −0.33, P , 0.37), as well as between 
HbA1c and both basal and maximum glucose-  stimulated trans-
port, although neither of them were   significant (r = −0.42, 
P , 0.25, and r = −0.37, P , 0.32 for basal and maximum 
glucose transport, respectively, Table 3).
Discussion
Glucose uptake is regulated by insulin in the case of high 
plasma glucose. Insulin is then secreted and stimulates the 
uptake and storage of glucose, as well as its metabolism 
in skeletal muscle and adipose tissue, in order to maintain 
a constant glucose level. In our study, the group with a 
longer disease duration had higher insulin requirements 
for metabolic control. Furthermore, a significant positive 
correlation was found between the time of disease and 
the dose of insulin required for treatment, which suggests 
that the appearance of insulin resistance occurs during the 
course of disease and becomes higher with longer duration 
of disease. The required insulin dose in patients with type 1 
diabetes constitutes a marker of insulin resistance.10,11 Other 
factors which   influence insulin action, such as suboptimal 
control, overweight, counter-regulatory hormone excess, or 
ketoacidosis, have been suggested as mechanisms for insulin 
resistance in patients with type 1 diabetes.12 In our study, 
there were no differences in BMI and metabolic control 
as assessed by the level of HbA1c, which could explain the 
difference in insulin action in type 1 diabetic patients with 
different durations of diabetes.
The first mechanism of insulin action is mediated by 
cell surface receptors which were described in 1971.13 
An   alteration in the binding of insulin to its receptor could 
explain an impairment of insulin action in diabetic patients. 
Studies of insulin action in type 1 diabetes have observed 
normal restored insulin action in these individuals. Although 
muscle tissue is the major peripheral target organ of   insulin, 
adipose tissue is another important one, and previous studies 
have demonstrated that glucose uptake induced by insulin 
in this tissue correlates with overall glucose utilization.10,11 
Moreover, in vitro experiments show that a reversal of hyper-
glycemia normalizes the insulin action in fat cells following 
insulin treatment.14 In addition, normal insulin sensitivity 
has also been reported in patients with type 1 diabetes in the 
preclinical stage of the disease. In subjects with newly diag-
nosed type 1 diabetes, a transient   normalization of insulin 
action may occur after initial insulin treatment. In patients 
with type 1 diabetes, partial recovery of C-peptide secre-
tion has been observed during the   honeymoon period.15,16 
We measured C-peptide levels, both at baseline and six 
minutes after stimulation with glucagon 1 mg intravenously, 
and an absence of insulin secretion was confirmed. There-
fore, our results support the hypothesis that factors other 
than endogenous insulin secretion must contribute to the 
increase in daily insulin requirements over the duration of 
the disease.
High glucose transport in adipocytes as the cause of the 
honeymoon period, without changes in insulin secretion, 
has been reported.17 An increase in basal glucose transport 
and maximally stimulated glucose transport during the early 
phase of diabetes could explain the low insulin requirement 
needed to achieve metabolic control during the first year of 
the disease. In conceptual agreement, we now report high 
glucose transport, both basal and maximal, in type 1   diabetic 
patients with a shorter duration of disease. We did not observe 
insulin resistance in our type 1 diabetic patients, because both 
basal and maximum insulin-stimulated glucose uptake were 
not decreased in type 1 diabetic patients when compared 
with the control group. Furthermore, we found a negative 
Table  3  correlations  between  several  clinical  and  analytical 
parameters and insulin action in adipocyte tissue in type 1 diabetes 
patients
Length of  
diabetes  
(months)
HbA1c Body mass   
index
% maximum  
insulin binding 
r = −0.70  
P , 0.05
r = −0.33  
P , 0.34
r = −0.35  
P , 0.35
Basal glucose  
transport, Fl/cel/s
r = −0.87  
P , 0.01
r = −0.42  
P , 0.25
r = −0.51  
P , 0.12
Maximal glucose  
transport after  
insulin-stimulated  
glucose transport, Fl/cel/s
r = −0.88  
P , 0.01
r = −0.37  
P , 0.32
r = −0.38  
P , 0.30
Table  2  Insulin  binding,  basal  glucose  transport,  and  insulin-
stimulated glucose transport in adipocytes from type 1 diabetic 
patients according to duration of disease
T1D # 5  
years group
T1D . 5  
years group
Control  
group
% maximum 125I-insulin  
binding B/50,000 cells
  6.2 ± 0.2a   5.4 ± 0.1   6.4 ± 1.3 
Basal U-(14c)-D-glucose  
transport Fl/cel/s
  94.4 ± 24a,b 43.5 ± 21   54.3 ± 31
Maximal U-(14c)-D-glucose  
transport insulin-stimulated  
glucose transport  
(10−7 mol/L insulin) Fl/cel/s 
184.2 ± 61a,b 74.2 ± 28 102.5 ± 47
Notes: Insulin binding is expressed as percentage of maximal 125I-insulin binding; basal 
glucose transport is expressed as basal U-(14c)-D-glucose transport, and insulin-
stimulated  glucose  transport  as  maximum  insulin-stimulated  (10−7  mol/L  insulin) 
glucose transport.  aP , 0.05 versus type 1 diabetes .5 years group;  bP , 0.05 
versus control group.International Journal of General Medicine
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correlation between insulin action and duration of disease 
in type 1 diabetic patients.
A limitation of our study is the low number of patients. 
Our results indicate that a longer duration of diabetes could 
lead to a decrease in insulin action in type 1 diabetic patients. 
In the early phase of the disease, an increase in glucose 
transport and maximal insulin glucose transport could explain 
the lower dose of insulin needed in type 1 diabetic patients in 
clinical practice. Moreover, a normal insulin action explains 
the frequent hypoglycemia seen in type 1 diabetes versus 
type 2 diabetes patients with high levels of insulin and low 
episodes of hypoglycemia.
In summary, type 1 diabetic patients are not insulin-
resistant, and the early phase of the disease is characterized 
by an increase in glucose transport, both basal and insulin-
stimulated. Further studies with larger number of patients 
are needed to confirm our results.
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